Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Exploratory clinical study of Inetetamab + Pyrotinib + Capecitabine in the neoadjuvant treatment of HER2-positive breast cancer that is not sensitive to the initial treatment of trastuzumab
Excerpt:...Pathological examination confirmed that it is HER-2 positive invasive breast cancer; (HER2 positive is defined as immunohistochemistry (IHC) 3+ or IHC 2+ and further application of in situ hybridization (ISH) detection is HER2 gene amplification), regardless of Hormone receptor status (ER and PR); 3. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A Phase II Study of pyrotinib combined with capecitabine plus anlotinib for HER2-Positive Metastatic Breast Cancer
Excerpt:...Patients with recurrent/metastatic breast cancer confirmed by pathological examination with positive HER2 expression; Positive expression of HER2 refers to those whose HER2 is positive by standard immunohistochemical staining (IHC) and/or fluorescence in situ hybridization (FISH) (verified by the researchers in the test center); 3. ...
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
Excerpt:...Histopathological and/or cytological confirmed Her2-positive locally advanced or metastatic breast cancer (IHC3+, or IHC2+ and ISH+) 7....
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer
Excerpt:...Objective to evaluate the intracranial tumor progression time of piratinib and capecitabine combined with brain radiotherapy for HER2 positive breast cancer patients with brain metastasis`Time of intracranial tumor progression...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
Excerpt:...The patient has been confirmed to be HER2 positive....
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients
Excerpt:...- Early stage operable HER2-positive primary breast cancer...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer
Excerpt:...- Must have received ≥ 1 prior trastuzumab (Herceptin®)-containing regimen (unless there is a contraindication) if tumor is HER2 positive (3+ by immunohistochemistry or amplified by fluorescent in situ hybridization [FISH])...
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer
Excerpt:...Pathological confirmation of triple negative or Her-2 positive or with more than 4 axillary lymph node metastasis 5....
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Maintenance treatment of capecitabine in patient with HER 2-positive and triple negative breast cancer: a randomized, open label, blank controlled, multicenter trial
Excerpt:...Breast cancer subtypes are HER-2 positive or triple negative breast cancer, and not accept the anti-target therapy; 8. ...
Less C2 evidence
Evidence Level:Sensitive: C3 – Early Trials
Title:
Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis
Excerpt:Summary survival curves reported the summary median PFS and overall survival were 7.9 months and 12.3 months. Subgroup analysis revealed that TKIs combined with capecitabine (TKI + Cap) regimens resulted in improved survival outcomes….TKIs therapy improved the survival outcomes of HER2-positive BCBM patients, especially when combined with capecitabine and tolerable AEs.
DOI:https://doi.org/10.1002/cam4.6180
